Current diagnostic imaging of pheochromocytomas and implications for therapeutic strategy (Review)

Čtvrtlík,Filip; Koranda,Pavel; Schovánek,Jan; Škarda,Jozef; Hartmann,Igor; Tüdös,Zbyněk

doi:10.3892/etm.2018.5871

Current diagnostic imaging of pheochromocytomas and implications for therapeutic strategy (Review)

Authors:
- Filip Čtvrtlík
- Pavel Koranda
- Jan Schovánek
- Jozef Škarda
- Igor Hartmann
- Zbyněk Tüdös
View Affiliations

Affiliations: Department of Radiology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic, Department of Nuclear Medicine, University Hospital and Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic, Department of Internal Medicine III‑Nephrology, Rheumatology and Endocrinology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic, Department of Clinical and Molecular Pathology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic, Department of Urology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic
Published online on: February 14, 2018 https://doi.org/10.3892/etm.2018.5871
Pages: 3151-3160
Copyright: © Čtvrtlík et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The topic of pheochromocytomas is becoming increasingly popular as a result of major advances in different medical fields, including laboratory diagnosis, genetics, therapy, and particularly in novel advances in imaging techniques. The present review article discusses current clinical, biochemical, genetic and histopathological aspects of the diagnosis of pheochromocytomas and planning of pre‑surgical preparation and subsequent surgical treatment options. The main part of the paper is focused on the role of morphological imaging methods (primarily computed tomography and magnetic resonance imaging) and functional imaging (scintigraphy and positron emission tomography) in the diagnosis and staging of pheochromocytomas.

View Figures

View References

1	Dahia PL: Pheochromocytoma and paraganglioma pathogenesis: Learning from genetic heterogeneity. Nat Rev Cancer. 14:108–119. 2014. View Article : Google Scholar : PubMed/NCBI
2	Lenders JW, Eisenhofer G, Mannelli M and Pacak K: Phaeochromocytoma. Lancet. 366:665–675. 2005. View Article : Google Scholar : PubMed/NCBI
3	Lam AK: Update on adrenal tumours in 2017 world health organization (WHO) of endocrine tumours. Endocr Pathol. 28:213–227. 2017. View Article : Google Scholar : PubMed/NCBI
4	Lloyd RV, Osamura RY, Klöppel G and Rosai J: WHO Classification of Tumours of Endocrine Organs. 4th. IACR; Lyon: 2017
5	Roman-Gonzalez A and Jimenez C: Malignant pheochromocytoma-paraganglioma: Pathogenesis, TNM staging and current clinical trials. Curr Opin Endocrinol Diabetes Obes. 24:174–183. 2017. View Article : Google Scholar : PubMed/NCBI
6	Amin B, Edge S and Greene F: AJCC cancer staging manual. Springer; New York: 2017, View Article : Google Scholar
7	Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K and Young WF Jr; Endocrine Society, : Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 99:1915–1942. 2014. View Article : Google Scholar : PubMed/NCBI
8	Crona J, Taïeb D and Pacak K: New perspectives on pheochromocytoma and paraganglioma: Towards a molecular classification. Endocr Rev. 38:489–515. 2017. View Article : Google Scholar : PubMed/NCBI
9	Pacak K and Del Rivero J: Pheochromocytoma (Updated June 10, 2013) = Endotext. De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, et al: MDText.com, Inc.; South Dartmouth, MA: 2000
10	Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, et al: Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 346:1459–1466. 2002. View Article : Google Scholar : PubMed/NCBI
11	Pacak K and Wimalawansa SJ: Pheochromocytoma and paraganglioma. Endocr Pract. 21:406–412. 2015. View Article : Google Scholar : PubMed/NCBI
12	Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, Lechleiter JD, Sass M, Aronin N, Schiavi F, et al: Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet. 42:229–233. 2010. View Article : Google Scholar : PubMed/NCBI
13	Tsirlin A, Oo Y, Sharma R, Kansara A, Gliwa A and Banerji MA: Pheochromocytoma: A review. Maturitas. 77:229–238. 2014. View Article : Google Scholar : PubMed/NCBI
14	Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN, et al: Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 287:848–851. 2000. View Article : Google Scholar : PubMed/NCBI
15	Niemann S and Müller U: Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet. 26:268–270. 2000. View Article : Google Scholar : PubMed/NCBI
16	Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, Sköldberg F, Husebye ES, Eng C and Maher ER: Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet. 69:49–54. 2001. View Article : Google Scholar : PubMed/NCBI
17	Karasek D, Shah U, Frysak Z, Stratakis C and Pacak K: An update on the genetics of pheochromocytoma. J Hum Hypertens. 27:141–147. 2013. View Article : Google Scholar : PubMed/NCBI
18	Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM and Pacak K: High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: Implications for genetic testing. J Clin Endocrinol Metab. 91:4505–4509. 2006. View Article : Google Scholar : PubMed/NCBI
19	Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, Ling S, et al: Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 31:181–193. 2017. View Article : Google Scholar : PubMed/NCBI
20	NGS, in PPGL (NGSnPPGL) Study Group, ; Toledo RA, Burnichon N, Cascon A, Benn DE, Bayley JP, Welander J, Tops CM, Firth H, Dwight T, et al: Consensus statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nat Rev Endocrinol. 13:233–247. 2017. View Article : Google Scholar : PubMed/NCBI
21	Zelinka T and Widimský J: Pheochromocytoma-why is its early diagnosis so important for patient? Vnitr Lek. 61:487–491. 2015.PubMed/NCBI
22	Pacak K, Linehan WM, Eisenhofer G, Walther MM and Goldstein DS: Recent advances in genetics, diagnosis, localization and treatment of pheochromocytoma. Ann Intern Med. 134:315–329. 2001. View Article : Google Scholar : PubMed/NCBI
23	Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV and Pacak K; North American Neuroendocrine Tumor Society (NANETS), : The North American neuroendocrine tumor society consensus guideline for the diagnosis and management of neuroendocrine tumors: Pheochromocytoma, paraganglioma and medullary thyroid cancer. Pancreas. 39:775–783. 2010. View Article : Google Scholar : PubMed/NCBI
24	Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS and Eisenhofer G: Biochemical diagnosis of pheochromocytoma: Which test is best? JAMA. 287:1427–1434. 2002. View Article : Google Scholar : PubMed/NCBI
25	Eisenhofer G, Siegert G, Kotzerke J, Bornstein SR and Pacak K: Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. Horm Metab Res. 40:329–337. 2008. View Article : Google Scholar : PubMed/NCBI
26	Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR and Pacak K: Biochemical diagnosis of pheochromocytoma: How to distinguish true-from false-positive test results. J Clin Endocrinol Metab. 88:2656–2666. 2003. View Article : Google Scholar : PubMed/NCBI
27	Jacques AE, Sahdev A, Sandrasagara M, Goldstein R, Berney D, Rockall AG, Chew S and Reznek RH: Adrenal phaeochromocytoma: Correlation of MRI appearances with histology and function. Eur Radiol. 18:2885–2892. 2008. View Article : Google Scholar : PubMed/NCBI
28	Motta-Ramirez GA, Remer EM, Herts BR, Gill IS and Hamrahian AH: Comparison of CT Findings in symptomatic and incidentally discovered pheochromocytomas. Am J Roentgenol. 185:684–688. 2005. View Article : Google Scholar
29	Čtvrtlík F, Heřman M, Študent V, Tichá V and Minařík J: Differential diagnosis of incidentally detected adrenal masses revealed on routine abdominal CT. Eur J Radiol. 69:243–252. 2009. View Article : Google Scholar : PubMed/NCBI
30	Patel J, Davenport MS, Cohan RH and Caoili EM: Can established CT attenuation and washout criteria for adrenal adenoma accurately exclude pheochromocytoma? AJR Am J Roentgenol. 201:122–127. 2013. View Article : Google Scholar : PubMed/NCBI
31	Schieda N, Alrashed A, Flood TA, Samji K, Shabana W and McInnes MD: Comparison of quantitative MRI and CT washout analysis for differentiation of adrenal pheochromocytoma from adrenal adenoma. AJR Am J Roentgenol. 206:1141–1148. 2016. View Article : Google Scholar : PubMed/NCBI
32	Zhang GM, Shi B, Sun H, Jin ZY and Xue HD: Differentiating pheochromocytoma from lipid-poor adrenocortical adenoma by CT texture analysis: Feasibility study. Abdom Radiol. 42:2305–2313. 2017. View Article : Google Scholar
33	McDermott S, McCarthy CJ and Blake MA: Images of pheochromocytoma in adrenal glands. Gland Surg. 4:350–358. 2015.PubMed/NCBI
34	Pacak K, Goldstein DS, Doppman JL, Shulkin BL, Udelsman R and Eisenhofer G: A ‘pheo’ lurks: Novel approaches for locating occult pheochromocytoma. J Clin Endocrinol Metab. 86:3641–3646. 2001. View Article : Google Scholar : PubMed/NCBI
35	Korobkin M, Giordano TJ, Brodeur FJ, Francis IR, Siegelman ES, Quint LE, Dunnick NR, Heiken JP and Wang HH: Adrenal adenomas: Relationship between histologic lipid and CT and MR findings. Radiology. 200:743–747. 1996. View Article : Google Scholar : PubMed/NCBI
36	Remer EM, Motta-Ramirez GA, Shepardson LB, Hamrahian AH and Herts BR: CT histogram analysis in pathologically proven adrenal masses. Am J Roentgenol. 187:191–196. 2006. View Article : Google Scholar
37	Lubner MG, Smith AD, Sandrasegaran K, Sahani DV and Pickhardt PJ: CT texture analysis: Definitions, applications, biologic correlates and challenges. RadioGraphics. 37:1483–1503. 2017. View Article : Google Scholar : PubMed/NCBI
38	Northcutt BG, Raman SP, Long C, Oshmyansky AR, Siegelman SS, Fishman EK and Johnson PT: MDCT of adrenal masses: Can dual-phase enhancement patterns be used to differentiate adenoma and pheochromocytoma? AJR Am J Roentgenol. 201:834–839. 2013. View Article : Google Scholar : PubMed/NCBI
39	Korobkin M, Brodeur FJ, Yutzy GG, Francis IR, Quint LE, Dunnick NR and Kazerooni EA: Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. AJR Am J Roentgenol. 166:531–536. 1996. View Article : Google Scholar : PubMed/NCBI
40	Caoili EM, Korobkin M, Francis IR, Cohan RH and Dunnick NR: Delayed enhanced CT of lipid-poor adrenal adenomas. AJR Am J Roentgenol. 175:1411–1415. 2000. View Article : Google Scholar : PubMed/NCBI
41	Szolar DH, Korobkin M, Reittner P, Berghold A, Bauernhofer T, Trummer H, Schoellnast H, Preidler KW and Samonigg H: Adrenocortical carcinomas and adrenal pheochromocytomas: Mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology. 234:479–485. 2005. View Article : Google Scholar : PubMed/NCBI
42	Kumagae Y, Fukukura Y, Takumi K, Shindo T, Tateyama A, Kamiyama T, Kamimura K and Nakajo M: Distinguishing adrenal adenomas from non-adenomas on dynamic enhanced CT: A comparison of 5 and 10 min delays after intravenous contrast medium injection. Clin Radiol. 68:696–703. 2013. View Article : Google Scholar : PubMed/NCBI
43	Mukherjee JJ, Peppercorn PD, Reznek RH, Patel V, Kaltsas G, Besser M and Grossman AB: Pheochromocytoma: Effect of nonionic contrast medium in CT on circulating catecholamine levels. Radiology. 202:227–231. 1997. View Article : Google Scholar : PubMed/NCBI
44	Bessell-Browne R and O'Malley ME: CT of pheochromocytoma and paraganglioma: Risk of adverse events with i.v. administration of nonionic contrast material. AJR Am J Roentgenol. 188:970–974. 2007. View Article : Google Scholar : PubMed/NCBI
45	Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y and Bornstein SR: The clinically inapparent adrenal mass: Update in diagnosis and management. Endocr Rev. 25:309–340. 2004. View Article : Google Scholar : PubMed/NCBI
46	Tsushima Y, Takahashi-Taketomi A and Endo K: Diagnostic utility of diffusion-weighted MR imaging and apparent diffusion coefficient value for the diagnosis of adrenal tumors. J Magn Reson Imaging. 29:112–117. 2009. View Article : Google Scholar : PubMed/NCBI
47	Umanodan T, Fukukura Y, Kumagae Y, Shindo T, Nakajo M, Takumi K, Nakajo M, Hakamada H, Umanodan A and Yoshiura T: ADC histogram analysis for adrenal tumor histogram analysis of apparent diffusion coefficient in differentiating adrenal adenoma from pheochromocytoma. J Magn Reson Imaging. 45:1195–1203. 2017. View Article : Google Scholar : PubMed/NCBI
48	Dong Y and Liu Q: Differentiation of malignant from benign pheochromocytomas with diffusion-weighted and dynamic contrast-enhanced magnetic resonance at 3.0 T. J Comput Assist Tomogr. 36:361–366. 2012. View Article : Google Scholar : PubMed/NCBI
49	Kim S, Salibi N, Hardie AD, Xu J, Lim RP, Lee VS and Taouli B: Characterization of adrenal pheochromocytoma using respiratory-triggered proton MR spectroscopy: Initial experience. AJR Am J Roentgenol. 192:450–454. 2009. View Article : Google Scholar : PubMed/NCBI
50	Melo HJ, Goldman SM, Szejnfeld J, Faria JF, Huayllas MK, Andreoni C and Kater CE: Application of a protocol for magnetic resonance spectroscopy of adrenal glands: An experiment with over 100 cases. Radiol Bras. 47:333–341. 2014. View Article : Google Scholar : PubMed/NCBI
51	Reimer P, Parizel PM and Stichnoth FA: Clinical MR imaging: A practical approach Second, completely revised and updated. Springer-Verlag; Berlin Heidelberg New York: 2006, View Article : Google Scholar
52	Shellock FG and Kanal E: Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging. 10:477–484. 1999. View Article : Google Scholar : PubMed/NCBI
53	Taïeb D, Timmers HJ, Hindié E, Guillet BA, Neumann HP, Walz MK, Opocher G, de Herder WW, Boedeker CC and de Krijger RR: EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 39:1977–1995. 2012. View Article : Google Scholar : PubMed/NCBI
54	Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, Moncayo R, Mortelmans L, Pepe G, Reske SN, et al: 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: Procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 37:2436–2446. 2010. View Article : Google Scholar : PubMed/NCBI
55	Treglia G, Cocciolillo F, de Waure C, Di Nardo F, Gualano MR, Castaldi P, Rufini V and Giordano A: Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: A meta-analysis. Eur J Nucl Med Mol Imaging. 39:1144–1153. 2012. View Article : Google Scholar : PubMed/NCBI
56	Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, Jager PL, Elsinga PH, Dierckx RA, van der Wal JE, et al: 6-(F-18)Fluoro-l-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with 123I-metaiodobenzylguanidine scintigraphy, computer tomography and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab. 94:3922–3930. 2009. View Article : Google Scholar : PubMed/NCBI
57	Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, King KS, Rao JU, Wesley RA, Adams KT and Pacak K: Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography. J Natl Cancer Inst. 104:700–708. 2012. View Article : Google Scholar : PubMed/NCBI
58	Janssen I, Chen CC, Millo CM, Ling A, Taieb D, Lin FI, Adams KT, Wolf KI, Herscovitch P, Fojo AT, et al: PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 43:1784–1791. 2016. View Article : Google Scholar : PubMed/NCBI
59	Jing H, Li F, Wang L, Wang Z, Li W, Huo L and Zhang J: Comparison of the 68Ga-DOTATATA PET/CT, FDG PET/CT and MIBG SPECT/CT in the evaluation of suspected primary pheochromocytomas and paragangliomas. Clin Nucl Med. 42:525–529. 2017. View Article : Google Scholar : PubMed/NCBI
60	Chang CA, Pattison DA, Tothill RW, Kong G, Akhurst TJ, Hicks RJ and Hofman MS: 68Ga-DOTATATE and ¹⁸F-FDG PET/CT in paraganglioma and pheochromocytoma: Utility, patterns and heterogeneity. Cancer Imaging. 16:2016. View Article : Google Scholar : PubMed/NCBI
61	Tato A, Orte L, Diz P, Quereda C and Ortuno J: Malignant pheochromocytoma, still a therapeutic challenge. Am J Hypertens. 10:479–481. 1997. View Article : Google Scholar : PubMed/NCBI
62	Strong VE, Kennedy T, Al-Ahmadie H, Tang L, Coleman J, Fong Y, Brennan M and Ghossein RA: Prognostic indicators of malignancy in adrenal pheochromocytomas: Clinical, histopathologic and cell cycle/apoptosis gene expression analysis. Surgery. 143:759–768. 2008. View Article : Google Scholar : PubMed/NCBI
63	Thompson LD: Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: A clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 26:551–566. 2002. View Article : Google Scholar : PubMed/NCBI
64	Mlika M, Kourda N, Zorgati MM, Bahri S, Ben Ammar S and Zermani R: Prognostic value of Pheochromocytoma of the adrenal gland scaled score (Pass score) tests to separate benign from malignant neoplasms. Tunis Med. 91:209–215. 2013.PubMed/NCBI
65	de Wailly P, Oragano L, Radé F, Beaulieu A, Arnault V, Levillain P and Kraimps JL: Malignant pheochromocytoma: New malignancy criteria. Langenbecks Arch Surg. 397:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
66	Duregon E, Volante M, Bollito E, Goia M, Buttigliero C, Zaggia B, Berruti A, Scagliotti GV and Papotti M: Pitfalls in the diagnosis of adrenocortical tumors: A lesson from 300 consultation cases. Hum Pathol. 46:1799–1807. 2015. View Article : Google Scholar : PubMed/NCBI
67	Ctvrtlik F, Koranda P and Tichy T: Adrenal disease: A clinical update and overview of imaging. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 158:23–34. 2014.PubMed/NCBI
68	Hodin R, Lubitz C, Phitayakorn R and Stephen A: Diagnosis and management of pheochromocytoma. Curr Probl Surg. 51:151–187. 2014. View Article : Google Scholar : PubMed/NCBI
69	Vanderveen KA, Thompson SM, Callstrom MR, Young WF Jr, Grant CS, Farley DR, Richards ML and Thompson GB: Biopsy of pheochromocytomas and paragangliomas: Potential for disaster. Surgery. 146:1158–1166. 2009. View Article : Google Scholar : PubMed/NCBI
70	Brunaud L, Nguyen-Thi PL, Mirallie E, Raffaelli M, Vriens M, Theveniaud PE, Boutami M, Finnerty BM, Vorselaars WM, Rinkes IB, et al: Predictive factors for postoperative morbidity after laparoscopic adrenalectomy for pheochromocytoma: A multicenter retrospective analysis in 225 patients. Surg Endosc. 30:1051–1059. 2015. View Article : Google Scholar : PubMed/NCBI
71	Perel Y, Schlumberger M, Marguerite G, Alos N, Revillon Y, Sommelet D, De Lumley L, Flamant F, Dyon JF, Lutz P, et al: Pheochromocytoma and paraganglioma in children: A report of 24 cases of the french society of pediatric oncology. Pediatr Hematol Oncol. 14:413–422. 1997. View Article : Google Scholar : PubMed/NCBI
72	Wang W, Li P, Wang Y, Wang Y, Ma Z, Wang G, Gao J and Zhou H: Effectiveness and safety of laparoscopic adrenalectomy of large pheochromocytoma: A prospective, nonrandomized, controlled study. Am J Surg. 210:230–235. 2015. View Article : Google Scholar : PubMed/NCBI